Related references
Note: Only part of the references are listed.CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma
John H. Baird et al.
BLOOD (2021)
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
Carlos Salama et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study
Giorgio Bozzi et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)
Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma A Review
Frederick L. Locke et al.
JAMA ONCOLOGY (2020)
THEMIS-SHP1 Recruitment by 4-1BB Tunes LCK-Mediated Priming of Chimeric Antigen Receptor-Redirected T Cells
Chuang Sun et al.
CANCER CELL (2020)
Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China
Qiurong Ruan et al.
INTENSIVE CARE MEDICINE (2020)
Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma
Jennifer N. Brudno et al.
NATURE MEDICINE (2020)
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Enli Liu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome
Yuying Liu et al.
SCIENCE IMMUNOLOGY (2020)
Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma
Sattva S. Neelapu et al.
BLOOD (2020)
Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra
Shashidhar S. Jatiani et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study
Corrado Campochiaro et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2020)
Clinical and immunological features of severe and moderate coronavirus disease 2019
Guang Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
Nirali N. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
Loretta J. Nastoupil et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Prognostic impact of dose, duration, and timing of corticosteroid therapy in patients with large B-cell lymphoma treated with standard of care axicabtagene ciloleucel (Axi-cel).
Paolo Strati et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Effective treatment of severe COVID-19 patients with tocilizumab
Xiaoling Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Cytokine release syndrome in severe COVID-19
John B. Moore et al.
SCIENCE (2020)
Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity
Caron A. Jacobson et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Frequency and spectrum of disease-causing variants in 1892 patients with suspected genetic HLH disorders
Vanessa Gadoury-Levesque et al.
BLOOD ADVANCES (2020)
Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma
Paolo Strati et al.
BLOOD ADVANCES (2020)
Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies
Kevin R. Parker et al.
CELL (2020)
Senolytic CAR T cells reverse senescence-associated pathologies
Corina Amor et al.
NATURE (2020)
Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy
Eduardo Huarte et al.
CLINICAL CANCER RESEARCH (2020)
Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19
Raphael Cauchois et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients
Kazusa Ishii et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Functional effects of chimeric antigen receptor co-receptor signaling domains in human regulatory T cells
Nicholas A. J. Dawson et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Building a CAR-Treg: Going from the basic to the luxury model
Isaac Rosado-Sanchez et al.
CELLULAR IMMUNOLOGY (2020)
Single cell RNA sequencing of human microglia uncovers a subset associated with Alzheimer's disease
Marta Olah et al.
NATURE COMMUNICATIONS (2020)
Tocilizumab for treatment of patients with severe COVID-19: A retrospective cohort study
Tariq Kewan et al.
ECLINICALMEDICINE (2020)
Anakinra for severe forms of COVID-19: a cohort study
Thomas Huet et al.
LANCET RHEUMATOLOGY (2020)
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study
Giulio Cavalli et al.
LANCET RHEUMATOLOGY (2020)
Tocilizumab in patients with severe COVID-19: a retrospective cohort study
Giovanni Guaraldi et al.
LANCET RHEUMATOLOGY (2020)
Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management
Martina Pennisi et al.
BLOOD ADVANCES (2020)
Emapalumab in Primary Hemophagocytic Lymphohistiocytosis
Jan-Inge Henter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
Kris M. Mahadeo et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells
Alexandre V. Hirayama et al.
BLOOD (2019)
CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response
Nicholas F. Kuhn et al.
CANCER CELL (2019)
Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators
Mohit Sachdeva et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy
Utkarsh H. Acharya et al.
EXPERT REVIEW OF HEMATOLOGY (2019)
Parabrachial Interleukin-6 Reduces Body Weight and Food Intake and Increases Thermogenesis to Regulate Energy Metabolism
Devesh Mishra et al.
CELL REPORTS (2019)
CAR-T efficacy: is conditioning the key?
Sattva S. Neelapu
BLOOD (2019)
CD22 blockade restores homeostatic microglial phagocytosis in ageing brains
John V. Pluvinage et al.
NATURE (2019)
A safe and potent anti-CD19 CAR T cell therapy
Zhitao Ying et al.
NATURE MEDICINE (2019)
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
Katrin Mestermann et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR
Sara Ghorashian et al.
NATURE MEDICINE (2019)
CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity
Ji Li et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts
Rosalie M. Sterner et al.
BLOOD (2019)
Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma
Max Topp et al.
BLOOD (2019)
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke et al.
LANCET ONCOLOGY (2019)
Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency
Judith Feucht et al.
NATURE MEDICINE (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation
Irena Kaplanov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Terry J. Fry et al.
NATURE MEDICINE (2018)
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
Sattva S. Neelapu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy
Elizabeth Louise Siegler et al.
HUMAN GENE THERAPY (2018)
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
Margherita Norelli et al.
NATURE MEDICINE (2018)
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Theodoros Giavridis et al.
NATURE MEDICINE (2018)
Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'
David T. Teachey et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Chimeric Antigen Receptor Therapy
Carl H. June et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome
Robert Q. Le et al.
ONCOLOGIST (2018)
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
Bianca D. Santomasso et al.
CANCER DISCOVERY (2018)
Cytokine release syndrome
Alexander Shimabukuro-Vornhagen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
IFN-gamma, IL-17A, or zonulin rapidly increase the permeability of the blood-brain and small intestinal epithelial barriers: Relevance for neuro-inflammatory diseases
Mohammed T. Rahman et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome
Verena Staedtke et al.
NATURE (2018)
The Role of Interleukin-1 in the Pathogenesis of Cancer and its Potential as a Therapeutic Target in Clinical Practice
Adi Litmanovich et al.
ONCOLOGY AND THERAPY (2018)
Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells
Naoki Horikawa et al.
CLINICAL CANCER RESEARCH (2017)
Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms
M. Ruella et al.
LEUKEMIA (2017)
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib
Cameron J. Turtle et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels
James N. Kochenderfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
Paul M. Ridker et al.
LANCET (2017)
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
P. M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
Juliane Gust et al.
CANCER DISCOVERY (2017)
Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia
Alyssa Carey et al.
CELL REPORTS (2017)
The Lifespan and Turnover of Microglia in the Human Brain
Pedro Reu et al.
CELL REPORTS (2017)
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy
Kevin A. Hay et al.
BLOOD (2017)
NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease
Sara Mastaglio et al.
BLOOD (2017)
Expression of a Chimeric Antigen Receptor Specific for Donor HLA Class I Enhances the Potency of Human Regulatory T Cells in Preventing Human Skin Transplant Rejection
D. A. Boardman et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2017)
Toxicities of chimeric antigen receptor T cells: recognition and management
Jennifer N. Brudno et al.
BLOOD (2016)
At The Bedside: Clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies
Olalekan O. Oluwole et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2016)
Macrophage activation syndrome in the era of biologic therapy
Alexei A. Grom et al.
NATURE REVIEWS RHEUMATOLOGY (2016)
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
David T. Teachey et al.
CANCER DISCOVERY (2016)
Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells
Zeguo Zhao et al.
CANCER CELL (2015)
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
James N. Kochenderfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee et al.
LANCET (2015)
IL-6 as a keystone cytokine in health and disease
Christopher A. Hunter et al.
NATURE IMMUNOLOGY (2015)
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
David L. Porter et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TIP
Michael Schwameis et al.
THROMBOSIS AND HAEMOSTASIS (2015)
Perforin and granzymes: function, dysfunction and human pathology
Ilia Voskoboinik et al.
NATURE REVIEWS IMMUNOLOGY (2015)
An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome
Scott W. Canna et al.
NATURE GENETICS (2014)
Multiple Roles for Astrocytes as Effectors of Cytokines and Inflammatory Mediators
Michael V. Sofroniew
NEUROSCIENTIST (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Marco L. Davila et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
IL-6 in Inflammation, Immunity, and Disease
Toshio Tanaka et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2014)
The role IL-1 in tumor-mediated angiogenesis
Elena Voronov et al.
FRONTIERS IN PHYSIOLOGY (2014)
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Jason A. Dubovsky et al.
BLOOD (2013)
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
David T. Teachey et al.
BLOOD (2013)
The Interleukin-1 Family: Back to the Future
Cecilia Garlanda et al.
IMMUNITY (2013)
Preclinical In Vivo Modeling of Cytokine Release Syndrome Induced by ErbB-Retargeted Human T Cells: Identifying a Window of Therapeutic Opportunity?
Sjoukje J. C. van der Stegen et al.
JOURNAL OF IMMUNOLOGY (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
Renier J. Brentjens et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Biomarkers of endothelial activation/dysfunction in infectious diseases
Andrea V. Page et al.
VIRULENCE (2013)
Role of Caspases in Cytokine-Induced Barrier Breakdown in Human Brain Endothelial Cells
M. Alejandro Lopez-Ramirez et al.
JOURNAL OF IMMUNOLOGY (2012)
The Neuropathology of Fatal Cerebral Malaria in Malawian Children
Katerina Dorovini-Zis et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
Prostaglandins and Inflammation
Emanuela Ricciotti et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2011)
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
Charles A. Dinarello
BLOOD (2011)
Gene expression profiling of peripheral blood mononuclear cells from children with active hemophagocytic lymphohistiocytosis
Janos Sumegi et al.
BLOOD (2011)
Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study
James Galea et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2011)
Synaptic Pruning by Microglia Is Necessary for Normal Brain Development
Rosa C. Paolicelli et al.
SCIENCE (2011)
Why not treat human cancer with interleukin-1 blockade?
Charles A. Dinarello
CANCER AND METASTASIS REVIEWS (2010)
Immunological and Inflammatory Functions of the Interleukin-1 Family
Charles A. Dinarello
ANNUAL REVIEW OF IMMUNOLOGY (2009)
Cytokine regulation of tight junctions
Christopher T. Capaldo et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2009)
Animal models of sepsis: Why does preclinical efficacy fail to translate to the clinical setting?
Alex Dyson et al.
CRITICAL CARE MEDICINE (2009)
Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease
Norihiro Nishimoto et al.
BLOOD (2008)
IFN-γ Synergizes With LPS to Induce Nitric Oxide Biosynthesis Through Glycogen Synthase Kinase-3-Inhibited IL-10
Chiou-Feng Lin et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2008)
Human-hemato-lymphoid-system mice: Opportunities and challenges
Markus G. Manz
IMMUNITY (2007)
CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells
Claudia M. Kowolik et al.
CANCER RESEARCH (2006)
IFN-γ enhances production of nitric oxide from macrophages via a mechanism that depends on nucleotide oligomerization domain-2
Sabine Totemeyer et al.
JOURNAL OF IMMUNOLOGY (2006)
Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes
A Bondanza et al.
BLOOD (2006)
The role of atrial natriuretic peptide in the immune system
AM Vollmar
PEPTIDES (2005)
Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia
C Imai et al.
LEUKEMIA (2004)
CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86
C Orabona et al.
NATURE IMMUNOLOGY (2004)
IL-1 is required for tumor invasiveness and angiogenesis
E Voronov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Targeting ICAM-1/LFA-1 interaction for controlling autoimmune diseases: designing peptide and small molecule inhibitors
ME Anderson et al.
PEPTIDES (2003)
Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15
RJ Brentjens et al.
NATURE MEDICINE (2003)
An animal model for human cellular immunotherapy: specific eradication of human acute lymphoblastic leukemia by cytotoxic T lymphocytes in NOD/scid mice
BA Nijmeijer et al.
BLOOD (2002)
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR zeta/CD28 receptor
J Maher et al.
NATURE BIOTECHNOLOGY (2002)
Activated T cells induce macrophages to produce NO and control Leishmania major in the absence of tumor necrosis factor receptor p55
M Nashleanas et al.
INFECTION AND IMMUNITY (2000)
Share Paper
